JP2009530424A - 小分子アポトーシスプロモーター - Google Patents
小分子アポトーシスプロモーター Download PDFInfo
- Publication number
- JP2009530424A JP2009530424A JP2009509903A JP2009509903A JP2009530424A JP 2009530424 A JP2009530424 A JP 2009530424A JP 2009509903 A JP2009509903 A JP 2009509903A JP 2009509903 A JP2009509903 A JP 2009509903A JP 2009530424 A JP2009530424 A JP 2009530424A
- Authority
- JP
- Japan
- Prior art keywords
- ring
- optionally substituted
- independently
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 B=C1N(**)C(C)CC(C)C(*)C1N(C*=N)C(C(C)(C)N(*)C(*)=O)=O Chemical compound B=C1N(**)C(C)CC(C)C(*)C1N(C*=N)C(C(C)(C)N(*)C(*)=O)=O 0.000 description 9
- UYDVOJJGDUNFBQ-RGBJRUIASA-N C#CC[C@@H](C(N(CCC1)[C@@H]1C(NC(CCC1)C2=C1CCC=C2)=O)=O)N Chemical compound C#CC[C@@H](C(N(CCC1)[C@@H]1C(NC(CCC1)C2=C1CCC=C2)=O)=O)N UYDVOJJGDUNFBQ-RGBJRUIASA-N 0.000 description 1
- SZUQIPWLDTWPJU-UHFFFAOYSA-N CC1C2C=CC=CC2CCC1 Chemical compound CC1C2C=CC=CC2CCC1 SZUQIPWLDTWPJU-UHFFFAOYSA-N 0.000 description 1
- FNYLWDCVEBWTMR-LLVKDONJSA-N CC[C@H](C1=C(C)CCCC1)NC=O Chemical compound CC[C@H](C1=C(C)CCCC1)NC=O FNYLWDCVEBWTMR-LLVKDONJSA-N 0.000 description 1
- VBSZYCBMNCICHO-LLVKDONJSA-N O=CN[C@H](CCC1)C2=C1CCC=C2 Chemical compound O=CN[C@H](CCC1)C2=C1CCC=C2 VBSZYCBMNCICHO-LLVKDONJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78461206P | 2006-03-21 | 2006-03-21 | |
US85497506P | 2006-10-27 | 2006-10-27 | |
PCT/US2007/064569 WO2007136921A2 (en) | 2006-03-21 | 2007-03-21 | Small molecule apoptosis promoters |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009530424A true JP2009530424A (ja) | 2009-08-27 |
JP2009530424A5 JP2009530424A5 (US07794700-20100914-C00152.png) | 2010-03-04 |
Family
ID=38723933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009509903A Withdrawn JP2009530424A (ja) | 2006-03-21 | 2007-03-21 | 小分子アポトーシスプロモーター |
Country Status (8)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014504296A (ja) * | 2010-12-16 | 2014-02-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
JP7455141B2 (ja) | 2019-04-05 | 2024-03-25 | へパジーン セラピューティクス (エイチケイ) リミテッド | アポトーシスタンパク質の阻害剤の二価拮抗薬 |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2574040C (en) | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
ATE477254T1 (de) | 2004-12-20 | 2010-08-15 | Genentech Inc | Pyrrolidine als inhibitoren von iap |
CA2598995C (en) * | 2005-02-25 | 2014-07-15 | Stephen M. Condon | Dimeric iap inhibitors |
JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Birドメイン結合化合物 |
BRPI0617751A2 (pt) | 2005-10-25 | 2011-08-02 | Aegera Therapeutics Inc | compostos de ligação do domìnio iap bir |
CA2632807A1 (en) | 2005-12-19 | 2007-09-20 | Genentech, Inc. | Inhibitors of iap |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
EP1996184A4 (en) * | 2006-03-21 | 2010-09-22 | Joyant Pharmaceuticals Inc | SMALL MOLECULAR APOPTOSIS PROMOTERS |
CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
US7985735B2 (en) | 2006-07-24 | 2011-07-26 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
EP2049524A2 (en) | 2006-07-24 | 2009-04-22 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
MX2009011783A (es) | 2007-04-30 | 2009-12-04 | Genentech Inc | Inhibidores de iap. |
JP2010528587A (ja) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法 |
JP2011529962A (ja) | 2008-08-02 | 2011-12-15 | ジェネンテック, インコーポレイテッド | Iapのインヒビター |
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
WO2011016576A1 (en) | 2009-08-04 | 2011-02-10 | Takeda Pharmaceutical Company Limited | Alanine derivatives as inhibitors of apoptosis proteins |
EP2784076A1 (en) | 2009-10-28 | 2014-10-01 | Joyant Pharmaceuticals, Inc. | Dimeric SMAC mimetics |
WO2011059731A1 (en) | 2009-10-29 | 2011-05-19 | Janssen Pharmaceutica Nv | Alkynyl derivatives useful as dpp-1 inhibitors |
WO2011098904A1 (en) | 2010-02-12 | 2011-08-18 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
WO2013058825A1 (en) * | 2011-04-07 | 2013-04-25 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
EP2882740B1 (en) * | 2012-08-09 | 2017-03-01 | Bristol-Myers Squibb Company | Iap antagonists |
PL405505A1 (pl) * | 2013-09-30 | 2015-04-13 | Warszawski Uniwersytet Medyczny | Zastosowanie pochodnej kwasu diaminodikarboksylowego jako inhibitora aktywności biologicznej IL-15 I IL-2 |
RU2685505C1 (ru) * | 2018-11-29 | 2019-04-19 | Михаил Владимирович Овчинников | Гетероциклические амиды тирозина, обладающие анальгетическим, противовоспалительным и противоотечным действием |
MX2022008874A (es) | 2020-01-20 | 2022-08-11 | Astrazeneca Ab | Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer. |
EP4308095A1 (en) | 2021-03-15 | 2024-01-24 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
JP4674231B2 (ja) * | 2004-03-01 | 2011-04-20 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 2量体小分子アポトーシス増強剤 |
CA2574040C (en) * | 2004-07-15 | 2014-05-06 | Tetralogic Pharmaceuticals Corporation | Iap binding compounds |
BRPI0617751A2 (pt) * | 2005-10-25 | 2011-08-02 | Aegera Therapeutics Inc | compostos de ligação do domìnio iap bir |
TWI504597B (zh) * | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
EP1996184A4 (en) * | 2006-03-21 | 2010-09-22 | Joyant Pharmaceuticals Inc | SMALL MOLECULAR APOPTOSIS PROMOTERS |
-
2007
- 2007-03-21 EP EP07759058A patent/EP1996184A4/en not_active Withdrawn
- 2007-03-21 WO PCT/US2007/064569 patent/WO2007136921A2/en active Application Filing
- 2007-03-21 CA CA002646186A patent/CA2646186A1/en not_active Abandoned
- 2007-03-21 JP JP2009509903A patent/JP2009530424A/ja not_active Withdrawn
- 2007-03-21 AU AU2007254033A patent/AU2007254033A1/en not_active Abandoned
- 2007-03-21 US US11/726,602 patent/US7807699B2/en not_active Expired - Fee Related
- 2007-03-21 BR BRPI0708942-2A patent/BRPI0708942A2/pt not_active IP Right Cessation
- 2007-03-21 MX MX2008012053A patent/MX2008012053A/es unknown
-
2010
- 2010-10-04 US US12/897,760 patent/US8222291B2/en not_active Expired - Fee Related
-
2012
- 2012-06-28 US US13/536,974 patent/US8586542B2/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014504296A (ja) * | 2010-12-16 | 2014-02-20 | アッヴィ・インコーポレイテッド | 抗ウイルス性化合物 |
JP7455141B2 (ja) | 2019-04-05 | 2024-03-25 | へパジーン セラピューティクス (エイチケイ) リミテッド | アポトーシスタンパク質の阻害剤の二価拮抗薬 |
Also Published As
Publication number | Publication date |
---|---|
US20080051389A1 (en) | 2008-02-28 |
US20130281385A1 (en) | 2013-10-24 |
AU2007254033A1 (en) | 2007-11-29 |
CA2646186A1 (en) | 2007-11-29 |
EP1996184A4 (en) | 2010-09-22 |
US8586542B2 (en) | 2013-11-19 |
WO2007136921A3 (en) | 2008-03-20 |
US7807699B2 (en) | 2010-10-05 |
US8222291B2 (en) | 2012-07-17 |
BRPI0708942A2 (pt) | 2011-06-14 |
WO2007136921A2 (en) | 2007-11-29 |
EP1996184A2 (en) | 2008-12-03 |
WO2007136921A8 (en) | 2008-10-23 |
US20120082640A1 (en) | 2012-04-05 |
MX2008012053A (es) | 2008-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7807699B2 (en) | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters | |
US8642554B2 (en) | Smac mimetic dimers and trimers useful as anti-cancer agents | |
EP2493879B1 (en) | Dimeric smac mimetics | |
JP5419468B2 (ja) | Iapのbirドメインに結合する化合物 | |
BRPI0617751A2 (pt) | compostos de ligação do domìnio iap bir | |
BRPI0711591A2 (pt) | composto de ligação de domìnio bir da iap | |
US20100317593A1 (en) | 2,3-dihydro-1h-indene compounds | |
Falkenstein et al. | Histamine H3 receptor antagonists with peptidomimetic (keto) piperazine structures to inhibit Aβ oligomerisation | |
CN110028508B (zh) | 一种抗肿瘤的重氮双环类细胞凋亡蛋白抑制剂 | |
EA014874B1 (ru) | Соединения для ингибирования апоптоза | |
RU2446170C2 (ru) | Соединения, связывающиеся с bir доменом iap | |
WO2011090316A2 (ko) | 세포사멸 유도 활성을 갖는 신규 피라지논 유도체 및 이를 포함하는 약학 조성물 | |
MX2008005477A (en) | Iap bir domain binding compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100113 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100113 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20100811 |